Business1 outlet
Novo Nordisk Boosts Forecast on Soaring GLP-1 Sales
Novo Nordisk has raised its financial forecast for the second time in 2024, driven by stronger-than-expected sales of its GLP-1 drugs used for obesity and diabetes treatment. The company's optimistic outlook reflects surging global demand for these medications, which have become increasingly popular for weight management.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
How does this lean?
Comments
0No comments yet. Say what you noticed in the coverage.
Trending